Etilevodopa hydrochloride (Standard)
Etilevodopa (hydrochloride) (Standard) is the analytical standard of Etilevodopa (hydrochloride). This product is intended for research and analytical applications. Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine[1][2][3].
For research use only. We do not sell to patients.
- Purity: 98%
- CAS No.: 39740-30-2
- Formula: C11H16ClNO4
- Molecular Weight:261.70
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 39740-30-2
-
Molecular Weight 261.70
-
Formula C11H16ClNO4
-
SMILES
N[C@@H](CC1=CC=C(O)C(O)=C1)C(OCC)=O.[H]Cl
-
Synonyms
L-DOPA ethyl ester hydrochloride (Standard); Levodopa ethyl ester hydrochloride (Standard)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Djaldetti R, et al. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Clin Neuropharmacol. 2003 Nov-Dec;26(6):322-6. [Content Brief]
[2]. Blindauer K, et al. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb;63(2):210-6. [Content Brief]
[3]. Haddad F, et al. Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease. Molecules. 2017 Dec 25;23(1). pii: E40. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Etilevodopa hydrochloride (Standard) Related Classifications
HY-116016AR Related Classifications
Powered by Bioz